Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

A View of Industry from the Inside

Mary Pinkowish  |  Issue: April 2011  |  April 13, 2011

Dr. Siegel says that during his time at the FDA, he was approached about developing a clinical research program at various universities, and he says this would have been another logical avenue for him to follow post-FDA. But, he says that an academic research position that follows immediately after a research fellowship is the more conventional path. He was not comfortable making the transition to academics at this stage in his career.

Nonetheless, the path that Dr. Siegel did choose and that put him in a senior group medical director position is a bit unusual for someone leaving the FDA. “People come out of the FDA all the time to enter industry,” he says. This usually means entering the regulatory side of the business. “A transition to the clinical side, like I made, is more unusual,” Dr. Siegel points out. “I knew I could do regulatory affairs, but what excites me is drug development and getting drugs that work better for patients.” The attractions on the clinical side include working on proof-of-concept studies, early- or late-stage drug development, phase III safety and efficacy studies, and helping determine how a drug will be approved and marketed, he says.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
TABLE 1: How rheumatologists in different environments spend their time*
click for large version
TABLE 1: How rheumatologists in different environments spend their time*

Snapshot: A Rheumatologist’s Life in Industry

“When I get called ‘Dr. Davis’ at work, I know I’m in trouble,” jokes Dr. Davis. “It’s always ‘John’ at the office. Physicians who are successful in the pharmaceutical industry are the ones who are able to work with multiple functions and can leave some of the ego at the door.”

The worlds of clinical or academic medicine and industry are vastly different, continues Dr. Davis. “In medicine, you pretty much do it all on your own. You’re in a silo, and you’re rewarded for going in-depth in one disease. In industry, you have to be multifaceted,” he continues. “You must be able to work with different groups, including clinical operations, regulatory affairs, legal affairs, different research groups, and the commercial departments. You function as one member of a cross-functional team.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“For me, it’s refreshing to work from a team approach,” he says.

Dr. Davis says that some days when he’s driving home, he’s amazed by the variety of activities he’s been involved in during the course of the day. “I work closely with bench research scientists from the discovery of a molecule to proof-of-concept studies to phase I and II clinical trials. I have the opportunity to influence the design of clinical trials and help interpret the data,” he says. On a given day, Dr. Davis says, he “might give clinical input to a research colleague on diagnostic issues or discuss business development with someone from our partnering group. I might help a colleague involved with phase III trials and look at data to see how well the treatment worked in all patients or in particular subsets of patients,” he notes as examples.

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:Career DevelopmentProfessional TopicsWorkforce Tagged with:Career developmentIndustryrheumatologist

Related Articles

    A Regulatory Leader in Rheumatology

    October 1, 2008

    Jeffrey Siegel, MD: A rare combination of clinical scientist and regulatory collaborator

    Paul Davis, MD, Steps Down as Editor-in-Chief of Clinical Rheumatology

    December 1, 2013

    Dr. Davis’ eight-year tenure at the international rheumatology journal marked by growth in number of submitted manuscripts, international reach, and global impact

    Fall 2021’s Awards, Appointments & Announcements in Rheumatology

    October 13, 2021

    Jeffrey Siegel, MD, Assumes New Position as Director for New Office of Drug Evaluation Sciences at the FDA On Feb. 16, Jeffrey Siegel, MD, became the director of the recently created Office of Drug Evaluation Sciences at the U.S. Food & Drug Administration (FDA). The move, he says, “puts together many of the different things…

    Beyond Awareness: August Is Psoriasis Action Month

    August 15, 2017

    This month, the National Psoriasis Foundation is urging patients and rheumatologists to take charge of psoriatic disease by setting ambitious treatment goals to achieve better health outcomes…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences